amotosalen has been researched along with 2019 Novel Coronavirus Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagri, A; Busch, MP; Corash, LM; Darst, O; de Assis, RR; Di Germanio, C; Felgner, PL; Gatmaitan, M; Khan, S; Martinelli, R; Mei, ZW; Rioveros, J; Robinson, PV; Seftel, D; Simmons, G; Stone, M; Tsai, CT; Von Goetz, M; Ward, D; Ziman, A | 1 |
| Arthaud, CA; Barlet-Excoffier, V; Bonneaudeau, B; Chavarin, P; Cognasse, F; Duchez, AC; Eyraud, MA; Hamzeh-Cognasse, H; Heestermans, M; Hequet, O; Legrand, D; Mooney, N; Morel, P; Prier, A; Richard, P; Rochette-Eribon, S; Shurko, N; Teyssier, F; Tiberghien, P | 1 |
| Bagri, A; Corash, LM; de Assis, RR; Felgner, PL; Gatmaitan, M; Khan, S; Martinaud, C; Robinson, PV; Seftel, D; Tsai, CT | 1 |
| Alandijany, TA; Azhar, EI; Bajrai, LH; Damanhouri, GA; El-Kafrawy, SA; Hassan, AM; Hindawi, SI; Tolah, AM | 1 |
| Bazhenov, AI; Bogdanova, AS; Borovkova, NV; Bulanov, AY; Chirkova, KS; Dolzhikova, IV; Dombrovskiy, EA; Drozdova, NE; Ganchin, VV; Gintsburg, AL; Godkov, MA; Kamalova, AR; Kostin, AI; Ladygina, EA; Logunov, DY; Lundgren, MN; Petrikov, SS; Shcheblyakov, DV; Shustov, VV; Volkov, SE | 1 |
| Abunada, Q; Alandijany, TA; Almalki, AA; Azhar, EI; Badawi, MA; Bayoumi, MM; Damanhouri, GA; El-Kafrawy, SA; Hassan, AM; Hindawi, SI; Picard-Maureau, M; Tolah, AM; Zowawi, HM | 1 |
6 other study(ies) available for amotosalen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
Topics: Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Serotherapy; Furocoumarins; Humans; Immunization, Passive; SARS-CoV-2 | 2022 |
Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology.
Topics: COVID-19; COVID-19 Serotherapy; Endothelial Cells; Humans; Interleukin-10; Interleukin-18; Interleukin-1beta; Interleukin-6; Interleukin-8; Pandemics; Technology; Tumor Necrosis Factor-alpha; Ultraviolet Rays | 2022 |
Characterization of antibodies to SARS-CoV-2 in lyophilized plasma prepared with amotosalen-UVA pathogen reduction.
Topics: Antibodies, Neutralizing; COVID-19; Furocoumarins; Humans; SARS-CoV-2 | 2023 |
Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.
Topics: COVID-19; Furocoumarins; Humans; Plasma; SARS-CoV-2; Transfusion Reaction; Treatment Outcome; Ultraviolet Therapy; Virus Inactivation | 2021 |
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
Topics: Antibodies, Neutralizing; Blood Safety; Blood-Borne Pathogens; COVID-19; COVID-19 Serotherapy; Furocoumarins; Humans; Immunization, Passive; Methylene Blue; Plasma; Riboflavin; SARS-CoV-2 | 2021 |
Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light.
Topics: Blood Component Removal; Blood Platelets; COVID-19; Furocoumarins; Humans; RNA, Viral; SARS-CoV-2; Ultraviolet Rays; Virus Inactivation | 2022 |